Drug profile · INN
vysribli
VYSRIBLI (PREVIOUSLY DENOSUMAB INTAS)
vysribli (VYSRIBLI (PREVIOUSLY DENOSUMAB INTAS)) is an FDA-listed pharmaceutical active ingredient.
EMA: approved Musculo-skeletal system (M05) M05BX04
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — vysribli
- Class
- Musculo-skeletal system (M05)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
vysribli (VYSRIBLI (PREVIOUSLY DENOSUMAB INTAS)) is an FDA-listed pharmaceutical active ingredient.
Key facts
INN vysribli
Brand VYSRIBLI (PREVIOUSLY DENOSUMAB INTAS)
Therapeutic class Musculo-skeletal system (M05)
ATC code M05BX04
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is vysribli?
vysribli (VYSRIBLI (PREVIOUSLY DENOSUMAB INTAS)) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for vysribli?
VYSRIBLI (PREVIOUSLY DENOSUMAB INTAS) is a marketed brand name for vysribli. Check FDA Drugs@FDA for the current US label holder and prescribing information.